Purpose GeWtinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that has dramatic eVects in selective patients with non-small cell lung cancer (NSCLC). A simple non-invasive method for predicting the eYcacy of geWtinib is preferable in clinical settings. In this study, we evaluated prospectively whether surfactant protein-A (SP-A) and -D (SP-D) may be new conventional predictors of the eYcacy of geWtinib treatment. Methods We measured serum SP-A and SP-D levels on days 0 and 29 in 40 patients with advanced NSCLC treated with 250 mg geWtinib daily. Eligibility criteria included performance status ·3, age ·80 years, and stage IIIB-IV disease. In addition, EGFR mutations were analyzed in 24 patients. Results Multivariate analysis showed that favorable progression-free survival (PFS) after geWtinib treatment was associated with adenocarcinoma and high serum SP-D levels before treatment. EGFR mutation analysis of 24 patients showed that 16 patients had exon 19 deletion and/or exon 21 point mutations. EGFR mutations were signiWcantly correlated with response to geWtinib and serum SP-D levels before treatment was signiWcantly high in patients with the EGFR mutations. Serum SP-A levels were not associated with PFS. Conclusions The present study showed that measurement of serum SP-D levels before treatment in patients with NSCLC may be a new surrogate marker for predicting the response to geWtinib.
Introduction
GeWtinib is an epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) that shows anti-tumor activity for patients with advanced non-small cell lung cancer (NSCLC). Several clinical patient factors, such as being East Asian, female, and non-smoker, and having adenocarcinoma are closely associated with the anti-tumor activity of geWtinib [1] [2] [3] . Recently, EGFR gene mutations were also found to predict response and survival in patients treated with geWtinib [4] [5] [6] [7] and these mutations were more frequently seen in patients with the above-described clinical factors [8] . Thus, EGFR mutations in tumor cells have become important information for predicting the eYcacy of geWtinib treatment. High-sensitivity detection methods to detect EGFR mutations have recently been developed [9] [10] [11] [12] . However, it is sometimes diYcult to obtain adequate tumor specimens to analyze EGFR mutations, because lung adenocarcinoma often occurs in peripheral areas of the lung.
Surfactant proteins A (SP-A) and D (SP-D) are lung-speciWc glycoproteins that are produced and secreted by normal alveolar type II cells and Clara cells [13, 14] . A positive response to geWtinib is more frequently observed in adenocarcinomas expressing thyroid transcription factor 1 (TTF-1), which is a transcription factor of surfactant proteins [15] . In addition, EGF is reported to induce the production of SP-A in fetal normal lung tissue and antisense EGFR mRNA or an EGFR-TKI is reported to inhibit the production of SP-A [16, 17] . In contrast, SP-D, which is well known as a marker of activity of interstitial lung diseases [18, 19] , has also been reported to be produced and secreted by lung cancers [20] [21] [22] and serum SP-D levels are correlated with the volume of lung cancer [23] . Considering these Wndings, we hypothesized that these serum surfactant proteins are regulated through the EGF signaling pathway in lung cancer and that geWtinib inhibits the production of surfactant proteins as well as the proliferation of cancer cells. The present study is designed to evaluate whether serum levels of surfactant proteins may be new and convenient surrogate biomarkers for predicting the eYcacy of geWtinib treatment in patients with advanced NSCLC.
Patients and methods

Patient selection and treatment
Eligibility criteria were as follows: histologically or cytologically conWrmed stage IIIA or IV NSCLC; age ·80 years; and Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 to 3. The major exclusion criteria were as follows: interstitial pneumonia or pulmonary Wbrosis; active concomitant or recurrent history of any malignancy; uncontrolled angina pectoris, myocardial infarction less than 3 months before the enrollment, or congestive heart failure; uncontrolled diabetes mellitus or hypertension; severe infection; intestinal paralysis or obstruction; any women with pregnancy or lactation; and other serious medical conditions. Prior radiation therapy and chemotherapy were to be completed at least 4 weeks before enrollment.
Patients received geWtinib at a dose of 250 mg/day. Treatment continued until disease progression or intolerable toxicities became apparent or the patient refused further treatment. All patients gave written informed consent. This study protocol was approved by the ethics committee of Nagasaki University School of Medicine and each institution, and performed in accordance with the Declaration of Helsinki (1995, revised in Edinburgh 2000).
Measurement of SP-A and SP-D levels
Serum SP-A and SP-D levels were measured immediately before and 4 weeks after the start of treatment (days 0 and 29). The serum samples were stored at ¡80°C until assaying. Levels were measured using a commercially available enzyme-linked immunosorbent assay kit (Yamasa Co., Choshi, Japan) according to the manufacturer's protocol. Clinical cut-oV levels for serum SP-A (43.8 ng/ml) and SP-D (110 ng/ml) in interstitial lung disease were used for categorizing the groups in the survival curves [24] .
Evaluation of tumor response and toxicities
The response to geWtinib treatment was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST) [25] . BrieXy, complete response was deWned as the disappearance of all known disease. Partial response (PR) was deWned as a 30% reduction from baseline in the sum of the longest diameters of the target lesions and a lack of disease progression in non-target lesions. Progressive disease (PD) was deWned as the development of any new lesions or an increase of 20% in the sum of the longest diameters of the target lesions. Patients with stable disease (SD) did not meet the criteria for PR or PD. We evaluated the best response in each patient within 6 weeks from the start of treatment. Toxicities were assessed according to the United States National Cancer Institute Common Toxicity Criteria (NCI-CTC, version 2) [26] .
Genetic analyses of EGFR
After additional approval for EGFR mutation analysis by the Committee for Ethical Issues in conjunction with the institutional review board at each institution, written informed consent was obtained from each patient. Genomic DNA was extracted from the paraYn-embedded specimens using DEXPAT TM reagent (Takara Bio, Inc., Shiga, Japan) from frozen tissue samples that were retrieved from transbronchial biopsies or surgically resected, bronchial lavages, and pleural eVusions using QuickGene DNA tissue kit S (FujiWlm, Tokyo, Japan) according to the manufacturer's protocol. Subsequently, the deletion in exon 19 and point mutation of L858R in exon 21 in EGFR were retrospectively analyzed, using the mutant-enriched polymerase chain reaction (PCR) to increase the sensitivity of these mutations [11, 27] . The deletion region in exon 19 was ampliWed by PCR with a GeneAmp PCR System 9700 thermal cycler (Applied Biosystems, Foster City, CA, USA) using 20 ng of genomic DNA in a 25-l reaction mixture containing 1£ GoTaq Green master mix (Promega, Madison, WI, USA) and 15 pmol each of forward primer: 5Ј-ATCCCAGAAGGTGAGAAAGATAAAATTC-3Ј and reverse primer: 5Ј-CCTGAGGTTCAGAGCCATGGA-3Ј. The ampliWcation protocol consisted of initial denaturation at 94°C for 5 min, followed by 35 cycles of denaturation at 94°C for 30 s, annealing for 30 s at 60°C, and extension at 72°C for 30 s, and Wnal extension at 72°C for 5 min. The 138-bp PCR products were digested with MseI (New England BioLabs, Inc., Beverly, MA, USA). After the digest was ampliWed under similar conditions (the number of cycles was changed from 35 to 15), the second PCR products were separated by 6% polyacrylamide gel electrophoresis (PAGE) (Nacalai Tesque, Kyoto, Japan) and visualized with an ultraviolet transilluminator (Alpha Innotech Co., San Leandro, CA, USA) after ethidium bromide (Nacalai Tesque, Kyoto, Japan) staining. Separately, the point mutation region in exon 21 was ampliWed by PCR using 15 pmol each of forward primer: 5Ј-CAGCCAGGAAC GTACTGGTGA-3Ј and reverse primer: 5Ј-TCCTGGTGT CAGGAAAATGCT-3Ј. The other contents of the PCR mixture and the ampliWcation protocol were the same as described above. The 130-bp PCR products were digested with MscI (New England BioLabs, Inc.). After the digest was ampliWed under similar conditions (forward primer changed to 5Ј-CGCAGCATGTCAAGATCACAGAT-3Ј), the second PCR products were digested with AsuI (Fermentas International, Inc., Ontario, Canada). The digests were then subjected to separation by 8% PAGE and visualized by ethidium bromide staining.
Statistical analysis
The primary endpoint of the present study was progressionfree survival (PFS), which was deWned as the time from the date of beginning the treatment to the date of disease progression or death, or the last follow-up. Secondary endpoints were overall survival (OS) and tumor response. The survival curves were plotted by the Kaplan-Meier method and their diVerence was determined by the log-rank test. The PFS was expressed as median survival time, one-year survival rate, and 95% conWdence interval (95% CI). The prognostic values to survival were analyzed by univariate or stepwise multivariate Cox regression analysis. A twotailed P < 0.05 was considered statistically signiWcant. All analyses were performed using the SPSS statistical software package (version 11.0 for Macintosh; SPSS, Inc., Chicago, IL, USA).
The SP-D levels were expressed as the median, 25th percentile, and 75th percentile values. The diVerence in SP-D levels was determined by the Mann-Whitney U test for comparisons between two groups and by the Steel-Dwass test for comparisons among more than two groups.
Results
Anti-tumor activity and toxicities
From February 2003 to March 2006, 40 patients with advanced NSCLC were enrolled in the present study. The patient characteristics at baseline are listed in Table 1 . Of these 40 patients, 45.0% were women, 35.0% had never smoked, and 87.5% had adenocarcinoma. Following geWtinib treatment, no patients showed CR, 8 patients (20.0%) showed PR, 18 patients (45%) showed SD, and 14 patients (35.0%) showed PD. The median PFS was 87 days (95% CI 44-130 days) and one-year PFS was 17.5% (95% CI 5.7-29.3%) (Fig. 1a) .
No severe toxicities were observed and no treatmentrelated death occurred in the present study. Three patients (7.9%) experienced grade 3 interstitial pneumonitis. In these patients, pneumonitis occurred after day 29 and SP-A and SP-D levels were not increased on day 29 compared to day 0. Of these three patients, one had a grade 3 skin erup- tion, one had grade 3 liver dysfunction, and one had grade 3 ileus. Skin eruptions less than grade 2 were observed in 12 patients. Diarrhea less than grade 2 was observed in 6 patients. There were no relationships between toxicities and surfactant proteins levels (data not shown).
Response and serum surfactant protein levels
We evaluated the relationship between the response to geWtinib and serum SP-A and SP-D levels before treatment. The patients with PR had higher serum SP-D levels before treatment compared to those with PD (median value, 94.9 ng/ml vs. 53.4 ng/ml; P < 0.05) and the patients with SD showed no signiWcant diVerence in serum SP-D levels before treatment compared to those with PR (Fig. 2a) . In contrast, serum SP-A levels were not related with response (data not shown). Next, we evaluated the change in serum SP-D levels between immediately before and 28 days after geWtinib treatment in 38 patients (Fig. 2b) . Two patients died on days 24 and 29 from disease progression, so these patients were excluded from analysis. The decrease in serum SP-D levels was more frequently seen in the patients with PR and SD compared to those with PD (median values, ¡25.4 and 4.2% vs. 29.5%; P < 0.05, each). There was no signiWcant diVerence in change in SP-D levels between the patients 
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with PR and those with SD. In contrast, the change in serum SP-A levels was not related with response (data not shown).
Progression-free survival and serum SP-D levels
In the univariate Cox's hazard analysis of PFS, the patients with adenocarcinoma, those with high serum SP-D levels before treatment, and those who had never smoked had favorable survival ( Table 2 ). The hazard ratio for PFS was 0.145 for adenocarcinoma (95% CI 0.048-0.439), 0.953 for an increase by 10 ng/ml in SP-D levels before treatment (95% CI 0.910-0.997), and 0.497 for never-smokers (95% CI 0.257-0.965). The sex of the patient did not show a signiWcant diVerence on survival. Progression-free survival curves were stratiWed by histology (Fig. 1b) , serum SP-D levels before treatment (Fig. 1c) , and smoking (Fig. 1d) . The grouping of serum SP-D levels was based on clinical cut-oV levels for serum SP-D (110 ng/ml) in interstitial lung disease and patients were divided into three groups. Better PFS was seen in patients with adenocarcinoma (P < 0.0001), those with high serum SP-D levels before treatment (P = 0.0006), and those who never smoked (P = 0.0350). In multivariate Cox's hazard analysis of PFS using the stepwise method, the patients with adenocarcinoma and high serum SP-D levels before treatment had a decreased risk of disease progression. The hazard ratio for PFS was 0.102 for adenocarcinoma (95% CI, 0.031-0.334; P = 0.0002) and 0.939 for serum SP-D levels increased by 10 ng/ml (95% CI, 0.892-0.989; P = 0.0170).
On the other hand, the serum SP-A and SP-D levels were not related with overall survival (data not shown).
Extension study of EGFR mutations
Because many investigators have reported after we began the study that EGFR mutations are closely associated with the anti-tumor activity of geWtinib, we performed an extension study to examine the relationship between serum SP-D levels and EGFR mutations in 24 patients, 9 men and 15 women with a median age of 64 years (range 40-77 years). The smoking status was 13 never-smokers and 11 currentor ex-smokers. All of the patients had adenocarcinomas. Following geWtinib treatment, 8 patients showed PR, 9 patients showed SD, and 7 patients showed PD.
In the extension study as well as in the original study, the patients with PR had higher serum SP-D levels before treatment compared to those with PD ( Fig. 3a; median value, 83.4 ng/ml vs. 39.0 ng/ml; P < 0.05). The decrease in serum SP-D levels 28 days after treatment was more frequently seen in the patients with PR and SD compared to those with PD ( Fig. 3b ; median values, ¡31.0 and ¡4.4% vs. 33.3%; P < 0.05, each).
EGFR mutations were detected in 16 out of the 24 patients (66.7%): L858R in 8 patients, exon 19 deletion in 4 patients, and both L858R and exon 19 deletion in 4 patients. The patients with EGFR mutations were 15 women and 1 man, and 7 never-smokers and 9 current-or ex-smokers. Of 
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the patients with EGFR mutations, 8 showed PR, 5 showed SD, and 3 showed PD, whereas of those with wild-type EGFR, none showed PR, 4 showed SD, and 4 showed PD. EGFR mutations were signiWcantly associated with response to geWtinib (P = 0.0192). The serum SP-D levels before treatment were signiWcantly higher in those with EGFR mutations than those with wild-type genes ( Fig. 4 ; median value, 76.1 ng/ml vs. 41.3 ng/ml; P = 0.0101). Of the patients with EGFR mutations, median PFS was 246 days and one-year PFS was 25.0%, whereas of those with wild-type EGFR, median PFS was 42 days and oneyear PFS was 0% (P = 0.0284). The serum SP-D level and mutation status were not related with overall survival in the extension study (data not shown).
Discussion
In the present study, we demonstrated that serum SP-D levels may predict the response to geWtinib treatment. The patients who showed high serum SP-D levels before treatment achieved better responses and PFS times. In addition, high serum SP-D levels were closely associated with EGFR mutations. Surfactant protein-D (SP-D) is the speciWc glycoprotein produced and secreted by normal alveolar type II cells and Clara cells, and it is responsible for the production of pulmonary surfactant protein [13, 14] . Most SP-D can be both broken down by pulmonary macrophages and reabsorbed into the lamellar structures of type II cells as the pulmonary surfactant protein, while the remainder of it is transferred into the circulating blood; serum SP-D is well known as a marker of activity of interstitial lung diseases [18, 19] .
The concentration of SP-D in pleural eVusion from patients with pulmonary adenocarcinoma has been reported to be extremely high and cancer cells isolated from the same patients expressed mRNA for SP-D [20] . Betz et al. [21] stated that reverse transcriptase-polymerase chain reaction analysis (RT-PCR) of surfactant proteins including SP-D was useful for detecting lymph node micrometastasis of pulmonary adenocarcinoma. Moreover, murine pulmonary tumor cells expressed SP-D mRNA and SP-D could be detected by immunostaining [22] . Thus, SP-D is produced and secreted not only by alveolar type II cells and Clara cells, but also by lung cancer cells. Ohyanagi et al. [28] reported that serum SP-D decreased in patients with response to geWtinib treatment; they consider that SP-D may be produced by NSCLC. In the present study, as the tumor size decreased during geWtinib treatment, serum SP-D level was reduced. A signiWcant relationship between decreasing tumor size and serum SP-D levels also suggested that lung tumor cells might produce SP-D.
The eYcacy of geWtinib was observed to be signiWcantly more frequent in patients with high serum SP-D levels before the treatment and that serum SP-D levels before treatment in the patients with EGFR mutations were signiWcantly higher than that in patients without mutations. Many reports have been published during the present study revealing that the sensitivity to geWtinib treatment is closely related to EGFR gene mutations [4] [5] [6] [7] . About 90% of the EGFR mutations are either the in-frame deletion in exon 19 or mutational L858R in exon 21 [29] . EGFR mutations are now considered to be the most important predictive factor of the eYcacy of geWtinib treatment. Most adenocarcinomas with the EGFR mutations were categorized as terminal respiratory unit (TRU)-type adenocarcinomas, which Yatabe et al. [15] have noted previously. In addition, they reported that the majority of adenocarcinomas with TRU morphology showed TTF-1 positive staining and TTF-1 is a transcription factor that regulates surfactant proteins. Considering these Wndings, we supposed that SP-D might be produced by TRU-type lung cancer cells. This hypothesis might be supported by the fact that serum SP-D levels before treatment were higher in the patients with EGFR mutations.
Several studies have evaluated the relationship between surfactant proteins and the EGFR signaling pathway and/or geWtinib. In these reports, epidermal growth factor might induce the production of SP-A in normal fetal lung tissue through ligand binding to the EGFR and antisense EGFR mRNA or an EGFR tyrosine kinase inhibitor was reported to inhibit the production of SP-A [16, 17] . We previously reported that geWtinib suppresses MUC5AC protein synthesis through the epidermal growth factor signaling pathway [30] . MUC5AC is a glycoprotein that is secreted into airways similarly to surfactant proteins and is derived from goblet cells. It is one of the principal gel-forming mucins shown to be induced by the epidermal growth factor family [31] . Considering the possibility of the EGF system regulating the production of those surfactant proteins and mucins, SP-D synthesis may be regulated through the EGFR signaling pathway and geWtinib could inhibit the production of SP-D. Further studies are needed to investigate the relationship between them.
Measurement of serum SP-D level is convenient compared to the detection of EGFR mutations. Various kinds of biopsy specimens have been used for detecting EGFR mutations. Recently, high-sensitivity methods to detect EGFR mutations have been commonly used with cytological specimens, such as sputum, bronchial lavage Xuid, and pleural eVusion [9] . However, it is sometimes diYcult to obtain adequate tumor specimens for analyzing EGFR mutations because most lung adenocarcinomas occur in the peripheral lung Weld. Recently, Kimura et al. [32] revealed the detection of EGFR mutations with the use of a highsensitivity method called the Scorpion AmpliWcation Refractory Mutation System (SARMS) assay in free plasma DNA from patients with metastatic NSCLC. On the other hand, Maheswaran et al. [33] reported the analysis of EGFR mutations by the SARMS assay targeting the circulating tumor cells collected from the peripheral blood samples of patients. They concluded that this assay is more sensitive than using free plasma DNA. However, these analyses are not convenient methods in clinical practice and cost-eVectiveness remains unclear. Thus, we consider that serum SP-D might be a relatively convenient surrogate marker to predict the eYcacy of geWtinib.
In conclusion, serum SP-D appears to be a surrogate predictive marker of the eYcacy of geWtinib in patients with NSCLC. Further investigations are needed to clarify the relationship between the production of SP-D and the EGFR signaling pathways.
